Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSA single-center chart review found colitis patients on semaglutide or liraglutide hit symptom remission far more often than matched controls. The effect is too large and too selection-prone to trust, but weight loss does not account for it.
In a US records study of nearly 38,000 matched adults with obesity, those who had bariatric surgery had about 60 percent lower cardiovascular risk than those on semaglutide. The catch is that the people who choose surgery are not the people who choose a shot.
A scoping review in the American Journal of Sports Medicine mapped the research behind six gray-market recovery peptides and found most of it comes from rats, with thin, uncontrolled human data and a documented heart-failure signal for MK-677.
A 1,226-person patient survey found that the more weight people lost on GLP-1 drugs, the more they reported sagging skin, hair loss, and facial hollowing, while preexisting inflammatory rashes improved. Both sides of the ledger rise with the same weight loss.
An Eli Lilly-funded claims study followed 22,512 people who started tirzepatide for weight. The persistence numbers beat the field, but the 10.5 percent weight loss rests on 808 selected patients.
A single-center review of 200 cancer patients taking a GLP-1 drug alongside platinum chemotherapy found upper-gut side effects in nearly two-thirds, mostly mild and manageable. With no comparison group, the scarier mortality gap reflects who was sicker, not what the drug did.
In a TriNetX records study, people on tirzepatide had 18 to 25 percent lower carpal tunnel risk than users of other weight drugs. The authors called it neuroprotective. The plainer reading is that a wrist under less weight has more room for the nerve.
A Japanese claims study of nearly 300,000 people with type 2 diabetes found GLP-1 drugs carried no higher risk of a blocked or paralyzed bowel than an SGLT2 comparator. The null rules out a large effect, not a small one.
A German team aimed an off-the-shelf peptide vaccine at the EWSR1-FLI1 fusion junction that drives Ewing sarcoma. The patient built durable T-cell immunity and stayed stable past 26 months. It is also a study of exactly one person.
A SELECT trial reanalysis showed semaglutide slowing a 25-protein blood score that predicts dementia risk. A Taiwan cohort found fewer diagnoses on GLP-1 drugs, but only in the vaguest category. Two studies, same day, and the gap between them is the story.
A designed peptide, WMX-8, plugged IL17RA and matched an approved anti-inflammatory antibody in cultured skin and immune cells. There is no animal or human data, and the oral, cheaper pitch behind it is untested.
A generative-AI pipeline (RFDiffusion, ProteinMPNN, AlphaFold2) designed a peptide, SCP-1, built to lock the immune sensor STING in its inactive shape. Delivered in an enzyme-responsive gel, it calmed chronic inflammation and sped healing of diabetic wounds in mice. It is a preclinical, locally delivered result with no human data.
A synthetic peptide, aMPC16-CA50, ruptures tumor cells in two pH-triggered steps, damaging the lysosome first and the outer membrane later. The lag makes the death immunogenic, and in mice the peptide made immune-checkpoint drugs work better. It is cell-and-mouse work, published in Nature, with no human data yet.
A GLP-1 drug widened the blood supply to insulin-making islets within minutes, but only in diabetic mice and only when nitric oxide was available, pointing to a weight-independent way the drug may help beta cells.
The FDA's compounding advisers scheduled a second peptide meeting for before the end of February 2027, covering melanotan II, GHK-Cu, LL-37, dihexa, and PEG-MGF. There is no date and no docket yet, and the panel's last round cleared peptides with zero human trials.